🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

A lot in #mmsm at ASCO. JNJ-5322 is likely the greatest innovation we have seen in a few years. Potential to disrupt our approach to immunotherapy even before we figure out the current players. ⁦J&J Innovative Medicine⁩ congratulations to the investigators meetings.asco.org/abstracts-pres…

ASHP thanks Rep. Sharice Davids for being a cosponsor of the Ensuring Community Access to Pharmacists Services Act (H.R. 3164), which will ensure seniors can continue to receive access to testing, treatment, and vaccinations for common infectious diseases from pharmacists.

And the fun starts! From @asco #asco25 press release Overall survival was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm. PFS pic below NEJM asco.org/about-asco/pre…

#ASCO25 #mmsm check out our education chapter: Current and Future Directions of Immunotherapies in Multiple Myeloma ASCO ➡️ ascopubs.org/doi/10.1200/ED… My section focused on upfront quad therapy and when to consider triplet based therapy, check summary tables and figures👇

First trial of CAR-T cell ca tx for solid tumor response: ASCO #ASCO25 Satricabtagene autoleucel (satri-cel)/CT041 demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit in patients with previously treated,

PTCy is here to stay 💪🏽 Dose optimization is the next step 🙌🏽 We initiated a pilot project exploring PTCy ⤵️ in patients receiving MUD HSCT for AML. Here is our abstract, now out in Journal of Clinical Oncology, the #ASCO25 supplement 👇🏽 ascopubs.org/doi/10.1200/JC…

Very helpful and benchmarking analysis to show that outpatient #CARtcell (axicel here) is similar to inpatient .. All our axicel and other #CARtcell are administered outpatient here at OU Health Stephenson Cancer Center , and I can say our results are similar to this abstract too #CellTherapy

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Grateful to serve a meal at the American Cancer Society Hope Lodge with the resident wellness/social committee and our PGY-2 oncology residents. 💙 Thankful for everyone who helped plan and serve. Your kindness made a real difference.

Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: pharmacokinetics and clinical outcomes. ascopubs.org/doi/10.1200/JC… #ASCO2025 #POSTER #Thesis-Great full to mentors Gaurav Prakash M.D. Pankaj Malhotra DrArihant@jain

Vincent Rajkumar Mayo Myeloma While many #CART centers are proficient in managing CRS & ICANS, we are all learning how best to evaluate & manage emerging late toxicities in the field. Fortunate to have ANASTASIA ZEKERIDOU and Navreet Chowla, MD, FACG bring their team expertise. Stay tuned for updates as we learn more.

Dr Ajai Chari shares the USCF guidelines for prevention and management of infections post BCMA BsAb and CAR T cells #mmsm #EHA2025 #EHA25

Presented at #EHA2025: Among patients undergoing stem-cell transplantation from matched related donors, cyclophosphamide plus cyclosporin led to significantly longer GVHD-free, relapse-free survival than standard prophylaxis. Full ALLG BM12 CAST phase 3 trial results:

PTCy is the standard, regardless of donor or conditioning. I haven’t given MTX (outside of 1703) since 2018. 🚫 Death due to GVHD <1% with PTCy and 7-8/8 PBSC grafts. Still room for improvement, mostly thru burden/relapse reduction.

Prophy dex with glofitamab (4 mg after 1st glofi & bid for 3 days after C1D8, C1D15, C2D1) with reduction in CRS from 63% in trial to 32%, all G1-2. Moving towards outpatient glofi. #18ICML #lymsm

🚨 Major congratulations! 🚨 Dr. Joseph McGuirk, Division Director of Hematologic Malignancies & Cellular Therapeutics, has been awarded the prestigious 2025 KCU Alumni Lifetime Achievement Award! A true pioneer in CAR T therapy and Malignant Hematology — well deserved! 👏🎉

🚨🚨Breaking News: The FDA has eliminated the Risk Evaluation and Mitigation Strategy (REMS) for all currently approved BCMA- and CD19-directed autologous CAR T therapies (including Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta)  What does this mean? 1) Easier

Excellently written Nature Medicine review, and honestly the best graphics re: CAR-T toxicities (inc. infections & SPMs) that I’ve ever seen 👏 these will be used in slide decks everywhere! Congrats Kai Rejeski Joshua Hill, MD Michael Jain and thanks for writing this! #MMsm #lymsm

The #FDA has extended its review of Blenrep (belantamab mafodotin) for relapsed/refractory #myeloma. New decision date: Oct 23, 2025. Learn what this means for myeloma patients: mmsm.link/46kWcST